Technology
Health
Pharmaceutical

Sage Therapeutics

$163.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$4.56 (-2.71%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell SAGE and other stocks, options, ETFs, and crypto commission-free!

About

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. Read More The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Employees
637
Headquarters
Cambridge, Massachusetts
Founded
2010
Market Cap
8.57B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
503.68K
High Today
$167.93
Low Today
$162.42
Open Price
$166.71
Volume
371.50K
52 Week High
$177.05
52 Week Low
$79.88

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2014 IPO
US

News

Yahoo FinanceMay 6

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on May 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 21,680 shares of its common stock, and 6,280 performance restricted stock units (PSUs) to six new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducem...

113
Yahoo FinanceMay 4

Edited Transcript of SAGE earnings conference call or presentation 2-May-19 12:00pm GMT

Q1 2019 SAGE Therapeutics Inc Earnings Call Cambridge May 5, 2019 (Thomson StreetEvents) -- Edited Transcript of SAGE Therapeutics Inc earnings conference call or presentation Thursday, May 2, 2019 at 12:00:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Jeffrey M. Jonas Sage Therapeutics, Inc. - CEO, President & Director * Jim...

8
Yahoo FinanceMay 2

SAGE Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 2, 2019 / SAGE Therapeutics, Inc. (NASDAQ: SAGE) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 2, 2019 at 8:00 AM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/C-E8F2D102FD8ED To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile. About Investor Network...

54

Earnings

-$3.38
-$2.37
-$1.37
-$0.36
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.